Strategy

Nightingale Health exists to make preventative healthcare accessible to everyone. Preventative healthcare means that people at risk of a chronic disease are found before the disease develops, their risk is reduced, and the change in the risk is measured. Fewer people then become ill, healthcare costs less, the burden on healthcare professionals eases, and more people live long and healthy lives.

Nightingale Health's strategy is to be the molecular data layer of preventative health: the foundation of validated disease risk on which healthcare providers and consumer health platforms can build their own preventative services. Nightingale Health provides the measurement, the validated disease risks and the blood values behind them; the customer embeds the test and its result in its own service.

The strategy focuses on two markets. The first is healthcare: national and regional healthcare systems, private and occupational healthcare providers, employers and insurers. Nightingale Health's blood test is in use in this market today, including nationwide in Finland. The second is consumer health: the platforms that combine sensor data, digital data and an AI coach into one picture of a person's health, and that are now adding blood tests to their services. In both markets, the customer receives the same Nightingale Health test, measured in Nightingale Health's own laboratories, and the same output: validated disease risk in addition to the blood values.

Nightingale Health's blood test is designed for this. It requires one blood sample, age and sex, and nothing else: no questionnaires and no other measurements. The sample can be taken as a venous sample in a clinic or with a finger prick at home, so the test fits both markets: a health check in a clinic, and a digital service whose users take the sample at home. The results are delivered digitally into the customer's own systems. The customer can present them in its own service, whether that is a clinician's report or a health app. When the test is repeated, the change in risk shows whether lifestyle changes or treatment are working, for one person and for a whole population. That creates the feedback loop preventative healthcare needs: detect risk, prevent disease, and measure whether the risk is falling.

Nightingale Health runs the measurement in its own laboratories in Finland, the United Kingdom, Japan, Singapore and the United States. Each laboratory uses the same technology and the same process, so results are comparable across laboratories and over time, wherever the sample is taken. Capacity grows by adding instruments and laboratories. Approvals for healthcare use are obtained market by market; today the test is approved in the European Economic Area, the United Kingdom, Japan and Singapore. The company sells globally to healthcare providers and health platforms and prices the test per sample.

The better the disease risks of the future are understood, the better prevention can be targeted and funded. Nightingale Health's strategy is to make that understanding available in healthcare and in the products people use every day.

Business targets for financial year 2026–2027

Nightingale Health’s business target for the financial year 2026–2027 is:

To achieve revenue of at least EUR 10 million

Mid-term business targets

To conclude an agreement to analyze two million samples annually in Europe
To conclude an agreement to analyze ten million samples annually in the United States or in Asia
To extend laboratory capacity in respective geographical areas to meet the analysis capacity required by the aforementioned agreements
To achieve positive EBITDA

Long-term business targets

To analyze 100 million blood samples from partnerships with the healthcare sector, health initiatives, and white label partners
To generate EUR 500 million in annual revenue from partnerships with the healthcare sector, health initiatives, and white label partners